Levoxyl Articles
53% jump in 1st-qtr profit for Abbott
15 April 2009
Harmful drug-drug interactions for thyroid medicines identified
15 September 2008
Revised monograph for levothyroxine to be issued in USA
4 August 2008
FDA moves to ensure thyroid drug potency
15 October 2007
USA
22 August 2005
FDA rates Lannett's levothyroxine AB
20 December 2004
King's 3rd-qtr profit plunges, may restate
8 November 2004
US uninsured "pay 78% more than best Rx prices"
1 November 2004
KV resolves a handful of legal matters
20 September 2004
Experts warn on levothyroxine potency differences
16 August 2004
King's 2nd-qtr net loss rockets 81%
16 August 2004
Stock Commentary - New York
5 July 2004
Abbott sees 13.9% rise in sales for 1st-qtr 2004
19 April 2004
Second FDA drug imports "blitz" finds 80% come from Canada
9 February 2004
Stock Commentary - New York
12 May 2003
King gets Orange Book patent for Levoxyl
5 May 2003
Stock Commentary - New York
5 August 2002
King Pharma posts 36% leap in earnings
5 August 2002
Abbott's Synthroid FDA approved
5 August 2002
Abbott to get Synthroid approval by August?
22 July 2002
King 2003 guidance predicts EPS of $1.66
8 July 2002
King Pharma predicts EPS of $1.66 in 2003
8 July 2002
Stock Commentary - New York
1 July 2002
King Pharma has 20 Levoxyl patents pending
1 July 2002
Abbott posts strong revenue growth for 2001, but charges hit
21 January 2002
Abbott sales up 26% though earnings slip
11 October 2001
Abbott sales up 26% though earnings slip
10 October 2001
Abbott files NDA for Synthroid
2 August 2001
King Pharmaceuticals 2nd-qtr earnings leap 77%
25 July 2001
FDA orders cutback on Synthroid distribution
16 July 2001
Abbott sales growth driven by pharma
13 July 2001
US seniors' Rx cost rises "are double inflation"
15 June 2001
Abbott challenged by Gray Panthers
5 June 2001
Synthroid may be removed from market
1 June 2001
FDA approves King's Levoxyl
30 May 2001
US consumer groups pledge more lawsuits
15 May 2001
Abbott to file NDA for Synthroid
3 May 2001
King Pharma profits more than double, driven by Altace
21 February 2001
Watson launches four new products
15 January 2001
BASF sells pharma business to Abbott Labs for $6.9 billion in cash
15 December 2000
BASF excited about prospects for D2E7, as rumor mill talks of pharma
15 November 2000
Shareholders approve merger of King Pharmaceuticals and Jones Pharma
4 September 2000
First levothyroxine NDA backed by FDA
25 August 2000
Knoll gets approval for Synthroid settlement
10 August 2000
US doctors wrote 9% more scripts last year
25 April 2000
Boots and BASF accused in Canada
29 February 2000
BASF Pharma hoping to catch up with top pharmaceutical companies
23 September 1999
BASF Pharma first-half sales up 9% and speeding up
21 September 1999
No wrongdoing by Knoll in Synthroid case
2 August 1999
Knoll agrees to pharmacy grant
22 July 1999
Third-party payers lead Rx payments
5 May 1999
BASF Pharma on lookout for partner?
3 February 1999
US Seniors "Pay Up To 1,407% More For Rx Drugs"
29 September 1998
Knoll To Comarket Genzyme's Thyrogen
21 August 1998
USA's Most-Dispensed Rx Drugs In April 1998
20 May 1998
BASF Not Looking To Sell Pharma Business
30 March 1998
BASF Profits Up But Pharma Growth Down
14 November 1997
Knoll To Settle Synthroid Lawsuit
22 August 1997
BASF/Knoll Faces Lawsuit In USA Over Synthroid
26 May 1997
Generic And Branded Thyroid Drugs "Equal"
23 April 1997
Levothroid Batches Recalled In Spain
17 June 1996
Premarin Heads Top-10 Prescription Drugs
1 April 1996
Boots Deal Strengthens Pharma At BASF
17 April 1995
BASF Pharma Sales Slip In 1994 Hit By Currencies
17 April 1995
Good Half-year For Boots But No News On Pharma
7 November 1994
Roberts Acquires Product Licenses
26 September 1994
BOOTS LOOKING MORE TO THE OTC SECTOR
13 June 1994
BOOTS HOPES TO SWAY CITY WITH RESULTS
7 June 1993
RECORD RESULTS FOR FOREST LABS
8 February 1993
ANALYST'S ESTIMATES OF US THIRD QTR EARNINGS
12 October 1992
SMALLER US COMPANIES POST GOOD RESULTS
18 May 1992
Showing 1-89 of 89 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
